NM_000059.4:c.5552T>G
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BP4_ModerateBP6_Very_Strong
The NM_000059.4(BRCA2):c.5552T>G(p.Ile1851Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000833 in 1,608,738 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★★).
Frequency
Consequence
NM_000059.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -10 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA2 | ENST00000380152.8 | c.5552T>G | p.Ile1851Ser | missense_variant | Exon 11 of 27 | 5 | NM_000059.4 | ENSP00000369497.3 | ||
BRCA2 | ENST00000530893.7 | c.5183T>G | p.Ile1728Ser | missense_variant | Exon 11 of 27 | 1 | ENSP00000499438.2 | |||
BRCA2 | ENST00000614259.2 | n.5552T>G | non_coding_transcript_exon_variant | Exon 10 of 26 | 2 | ENSP00000506251.1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152162Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000444 AC: 11AN: 247934Hom.: 0 AF XY: 0.0000447 AC XY: 6AN XY: 134092
GnomAD4 exome AF: 0.0000872 AC: 127AN: 1456576Hom.: 0 Cov.: 44 AF XY: 0.0000787 AC XY: 57AN XY: 723980
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152162Hom.: 0 Cov.: 33 AF XY: 0.0000404 AC XY: 3AN XY: 74304
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 2 Uncertain:2Benign:3
IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.00059 -
- -
- -
- -
- -
not provided Uncertain:1Benign:3
- -
- -
In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 22703879, 16683254, 22366370, 27376475, 24817641, 20167696, 18403564, 31131967) -
BRCA2: BP4 -
not specified Uncertain:1Benign:2
Variant summary: BRCA2 c.5552T>G (p.Ile1851Ser) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 5.2e-05 in 269076 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in BRCA2 causing Hereditary Breast And Ovarian Cancer Syndrome (5.2e-05 vs 0.00075), allowing no conclusion about variant significance. c.5552T>G has been reported in the literature in individuals affected with breast cancer and/or ovarian cancer (Levanat_2012, Schenkel_2016). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. The variant has also been reported in two cancer-free individuals older than age 70 (FLOSSIES database), suggesting a non-pathogenic role. At-least one co-occurrence with another pathogenic variant(s) have been reported in the BIC database (BRCA2 c.5351dupA, p.Asn1784fsX3), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Multiple clinical diagnostic laboratories and an expert panel (ENIGMA) have submitted clinical-significance assessments for this variant to ClinVar after 2014 with a predominant consensus as benign (including the expert panel)/likely benign (n=7) (VUS, n=2). Based on the evidence outlined above, the variant was classified as benign. -
The BRCA2 c.5552T>G; p.Ile1851Ser variant (rs80358776), to our knowledge, has not been described in the medical literature but contains an entry in ClinVar (Variation ID: 37972). It is observed in the European (Non-Finnish) population at an overall frequency of 0.01% (11/110504 alleles) in the Genome Aggregation Database. The isoleucine at codon 1851 is weakly conserved, and computational algorithms (PolyPhen-2, SIFT) predict that this variant is tolerated. However, due to lack of clinical and functional data regarding this variant, its clinical significance cannot be determined with certainty. -
- -
Hereditary cancer-predisposing syndrome Benign:3
- -
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Breast and/or ovarian cancer Benign:1
- -
BRCA2-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Hereditary breast ovarian cancer syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at